article thumbnail

Merck launches accelerator programme for AI startups

pharmaphorum

The exploratory research phase for DSP-1181 was less than a year, compared to the average of five years using traditional drug design processes, according to the two developers. However, most novel active compounds identified with the help of AI are still in discovery or preclinical stages of development.

article thumbnail

Merck buys into Orion prostate cancer therapy in $290m deal

pharmaphorum

Merck – known as MSD outside the US and Canada – is paying $290 million upfront for global co-development and co-marketing rights to ODM-208, a steroid synthesis inhibitor, as well as follow-up compounds in the same class. Further financial terms have not been disclosed.

article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development.

Vaccines 126